Orphan designation: lusvertikimab Treatment of acute lymphoblastic leukaemia, 25/07/2023 Positive
European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting, European Medicines Agency, Amsterdam, the Netherlands, from 27 February 2024 to 28 February 2024
Work plan for the CVMP Novel Therapies & Technologies Working Party (NTWP) 2024
Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG), European Medicines Agency, Amsterdam, the Netherlands, 29 January 2024
Work plan for the Committee for Veterinary Medicinal Products (CVMP) Scientific Advice Working Party (SAWP-V) for 2024
Scientific advice and protocol assistance adopted during the CHMP meeting 22-25 January 2023
Start of Union reviews adopted during the CHMP meeting of 22-25 January 2024
Work plan for the Committee for Veterinary Medicinal Products (CVMP) Environmental Risk Assessment Working Party (ERAWP) 2024
Work plan for the Committee for Medicinal Products for Veterinary Use (CVMP) Pharmacovigilance Working Party (PhVWP-V) 2024
2023/2024 Work plan for the European Sales and Use of Antimicrobials in veterinary medicine Working Group (ESUAvet WG)